Raise closed, search for fresh raises on Seedstage

Reno, NV

Raising funds to advance treatments for neuromuscular disorders through innovative regenerative therapies.

• Mission: Advancing innovative regenerative therapies to treat the root causes of neuromuscular disorders like Muscular Dystrophy, Sarcopenia, and Cachexia, with the aim of improving quality of life and longevity for affected individuals.  
• Innovation: Utilizing cutting-edge biotechnology, Sarcomatrix focuses on muscle regeneration through small molecule α7β1 integrin activators and proteins, along with gene editing technologies, to address muscle-wasting diseases.  
• Clinical Advancement: Sarcomatrix is preparing for human clinical trials of its lead compound, S-969, supported by NIH grants, to demonstrate its efficacy and move towards FDA approval.  
• Strategic Focus: The funds raised will support the scale-up of manufacturing, clinical trial preparation, and ongoing research to bring the breakthrough therapies to market.  
• Patient-Centered Approach: Sarcomatrix works closely with patient advocacy groups, involving affected individuals and families throughout the drug development process to ensure their needs and concerns are addressed.  
• Leadership and Vision: With a visionary leadership team and a commitment to innovation, Sarcomatrix aims to become a leader in treating neuromuscular disorders and transforming the lives of those impacted by these conditions.  

Sarcomatrix Therapeutics is raising funds to advance its mission of tackling neuromuscular disorders, including Muscular Dystrophy, Sarcopenia, and Cachexia, through an innovative approach focused on treating the root causes rather than just symptoms. With a visionary leadership team and foundational support from NIH grants, Sarcomatrix seeks to move forward into human clinical trials, aiming to demonstrate the efficacy of their lead compound, S-969, and ultimately work toward FDA approval.

The funds raised in this offering will support critical steps in the regulatory and clinical trial preparation process, along with the scale-up of manufacturing capabilities and additional research and development efforts. Sarcomatrix is uniquely positioned to address a significant need in the biotechnology space, providing hope for improved quality of life and longevity for patients affected by these severe conditions through groundbreaking muscle regeneration therapies.

Company Info

Sarcomatrix develops treatments for muscular dystrophy and related muscle-wasting diseases through innovative biotechnology.

Sarcomatrix is a biotechnology company focused on developing effective treatments for individuals living with muscular dystrophy and other muscle-wasting diseases. The company leverages scientific advancements in muscle regeneration, specifically targeting muscular dystrophies, cachexia, and sarcopenia. Sarcomatrix’s research emphasizes the interaction between muscle cells and the extracellular matrix (ECM), which supports muscle fiber function.

Their innovative platform includes small molecule α7β1 integrin activators and proteins, which may be utilized alongside gene editing and therapy technologies. The company actively involves affected individuals and families throughout the drug development process, collaborating with patient advocacy groups to keep the community informed. Sarcomatrix aims to improve the quality of life for those impacted by muscular dystrophy through its commitment to advancing research and therapies.